Company:  CEMPRA, INC. (CEMP)
Form Type:  8-K/A
Filing Date:  10/24/2012 
CIK:  0001461993 
Address:  6320 QUADRANGLE DRIVE
SUITE 100
 
City, State, Zip:  CHAPEL HILL, North Carolina 27517-8149 
Telephone:  919-313-6617 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$9.94  
Change: 
0.02 (0.20%)  
Trade Time: 
Apr 24  
Market Cap: 
$330.01M
Description of Business
We are a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet critical medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. Our goal is to develop antibiotics with broad therapeutic potential and the right spectrum of activity to target pathogenic bacteria in adults and children. Broad therapeutic potential means addressing several disease indications. The right spectrum of activity means that, in addition to having activity against bacteria that have become resistant to many currently available antibiotics, the drug does not cause collateral damage to important bacteria such as intestinal microflora so that unintended side effects do not occur. Our lead product, solithromycin (CEM-101), is in Phase 3 clinical trials.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K/A
    SECTION 1 BUSINESS AND OPERATIONS
      Item 1.01. Entry into a Material Definitive Agreement.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURES
  EXHIBIT 4.8
  EXHIBIT 10.10
BROKERAGE PARTNERS